Assignee
BIOVERATIV THERAPEUTICS INC
US·69 granted patents·67 pending applications·296 citations·filing 2013–2025
Top patents by PatentIndex Score
136 records- 0198US9867873B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted Jan 16, 2018·17 cites·25 claims
- 0298US9675676B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Jun 13, 2017·19 cites·30 claims
- 0398US9629903B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·17 cites·29 claims
- 0498US9623091B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Apr 18, 2017·16 cites·28 claims
- 0597US10898554B1Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Jan 26, 2021·6 cites·22 claims
- 0696US10568943B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Feb 25, 2020·6 cites·18 claims
- 0795US11642398B2Factor IX polypeptide formulationsBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted May 9, 2023·4 cites·19 claims
- 0895US10548954B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·5 cites·16 claims
- 0995US9636416B2Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted May 2, 2017·20 cites·22 claims
- 1094US11266720B2Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 8, 2022·6 cites·64 claims
- 1194US10138291B2Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Nov 27, 2018·30 cites·36 claims
- 1293US11192936B2Factor VIII chimeric proteins and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted Dec 7, 2021·10 cites·58 claims
- 1393US11091534B2Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Aug 17, 2021·8 cites·20 claims
- 1493US10881742B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·5 cites·26 claims
- 1593US10561714B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Feb 18, 2020·3 cites·20 claims
- 1691US10370431B2Optimized factor VIII geneBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Aug 6, 2019·6 cites·16 claims
- 1791US10023628B2Cell line expressing single chain factor VIII polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jul 17, 2018·6 cites·17 claims
- 1890US11286528B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 29, 2022·4 cites·14 claims
- 1990US11008561B2Optimized factor IX geneBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted May 18, 2021·4 cites·22 claims
- 2090US9725496B1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Aug 8, 2017·4 cites·27 claims
- 2189US10745680B2Factor IX fusion proteins and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·6 cites·27 claims
- 2289US10548953B2Factor VIII-XTEN fusions and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Feb 4, 2020·6 cites·17 claims
- 2389US10001495B2Blood factor monitoring assay and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jun 19, 2018·6 cites·22 claims
- 2488US12186375B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Jan 7, 2025·1 cites·19 claims
- 2588US11370827B2Chimeric factor VIII polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jun 28, 2022·5 cites·48 claims
- 2688US11225650B2Methods of using FIX polypeptidesBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Jan 18, 2022·5 cites·20 claims
- 2787US11753461B2Optimized factor VIII genesBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Sep 12, 2023·3 cites·15 claims
- 2887US11168125B2Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Nov 9, 2021·1 cites·10 claims
- 2987US10786554B2Factor VIII polypeptide formulationsBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Sep 29, 2020·5 cites·42 claims
- 3086US12275970B2Optimized factor IX geneBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Apr 15, 2025·1 cites·15 claims
- 3186US10588949B2Factor IX polypeptide formulationsBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Mar 17, 2020·8 cites·42 claims
- 3286US2025195620A1Factor viii chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3384US2023023927A1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3483US11787851B2Optimized factor VIII geneBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Oct 17, 2023·1 cites·12 claims
- 3583US10058480B2Device containerBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Aug 28, 2018·10 cites·21 claims
- 3682US10221455B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Mar 5, 2019·5 cites·25 claims
- 3782US2025136640A1On-column viral inactivation methodsBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3882US2024212861A1Population pharmacokinetics tools and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3982US2022010000A1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4081US11578098B2On-column viral inactivation methodsBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Feb 14, 2023·1 cites·20 claims
- 4181US11372008B2Blood factor monitoring assay and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Jun 28, 2022·1 cites·9 claims
- 4281US10927362B2Processable single chain molecules and polypeptides made using sameBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Feb 23, 2021·1 cites·14 claims
- 4381US10287564B2Procoagulant compoundsBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted May 14, 2019·5 cites·11 claims
- 4480US12134632B2On-column viral inactivation methodsBIOVERATIV THERAPEUTICS INC·Filed 2023·Granted Nov 5, 2024·0 cites·21 claims
- 4580US10391152B2Methods of using a fixed dose of a clotting factorBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Aug 27, 2019·5 cites·14 claims
- 4680US2024141019A1Optimized factor viii geneBIOVERATIV THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4779US10772942B2Lyophilized factor IX formulationsBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted Sep 15, 2020·5 cites·10 claims
- 4878US10370430B2Recombinant factor VIII proteinsBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Aug 6, 2019·3 cites·20 claims
- 4978US2021277378A1Coagulation factor ix compositions and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5077US10611794B2On-column viral inactivation methodsBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Apr 7, 2020·2 cites·41 claims
Showing the top 50 of 136 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BIOVERATIV THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →